Copyright
©The Author(s) 2015.
World J Gastroenterol. Mar 21, 2015; 21(11): 3282-3290
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3282
Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3282
Table 2 Characteristics of patients who achieved steroid-free clinical remission under anti-tumor necrosis factor alpha treatment and of patients who did not achieve remission
Variable | remission (n = 16) | no remission (n = 56) | P value (univariate) | P value (multivariate) |
Age, (yr) | 32 (15-58) | 34 (18-71) | 0.755 | 0.685 |
Sex (female: male) | 11:5 | 28:28 | 0.184 | 0.560 |
Disease extent according to Montréal (E1:E2:E3) | 1:7:8 | 4:25:27 | 0.988 | |
Disease duration, (mo) | 69.5 (7-288) | 66 (2-480) | 0.968 | 0.873 |
Patients with extraintestinal manifestations | 6 (37.5) | 24 (42.9) | 0.338 | |
Smoking (active:non-smokers: ex-smokers) | 2:9:2 (n = 13) | 4:45:3 (n = 52) | 0.318 | |
BMI, (kg/m2) | 23.9 (18.9-30.8) | 24.2 (17.3-61.9) (n = 53) | 0.654 | 0.546 |
Previous medications | ||||
Purine analogons | 14 (87.5) | 42 (75.0) | 0.289 | |
Methotrexate | 4 (25.0) | 8 (14.3) | 0.310 | |
Calcineurin inhibitors | 2 (12.5) | 5 (8.9) | 0.671 | |
Concomitant medications | ||||
Steroids, (at start of treatment) | 12 (75.0) | 40 (71.4) | 0.778 | |
5-ASA | 12 (75.0) | 40 (71.4) | 0.778 | |
Purine analogons | 4 (25.0) | 20 (35.7) | 0.423 | |
Laboratory parameters before start of treatment with anti-TNFα | ||||
CrP, (mg/L) | 7.9 (0-45.3) (n = 14) | 3.1 (0-88.9) (n = 55) | 0.104 | |
Leukocyte number, (G/L) | 8.8 (3.6-16.6) (n = 14) | 8.8 (2.7-22.0) (n = 55) | 0.817 | |
Hemoglobin, (g/dl) | 11.3 (8.3-13.9) (n = 14) | 12.4 (9.0-17.0) (n = 55) | 0.023 | 0.561 |
MCV, (fl) | 82.5 (65-105) (n = 14) | 87 (61-112) (n = 55) | 0.374 | |
Platelet number, (G/L) | 408 (233-666) (n = 14) | 333 (150-850) (n = 55) | 0.114 | |
Albumin concentration, (g/L) | 41.5 (26.6-45.1) (n = 9) | 43.9 (36.0-48.8) (n = 44) | 0.009 | 0.034 |
Ferritin concentration, (μg/L) | 17 (2-201) (n = 8) | 27.5 (5-489) (n = 34) | 0.223 |
- Citation: Baki E, Zwickel P, Zawierucha A, Ehehalt R, Gotthardt D, Stremmel W, Gauss A. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol 2015; 21(11): 3282-3290
- URL: https://www.wjgnet.com/1007-9327/full/v21/i11/3282.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i11.3282